Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Receivables (2016 - 2025)

Lexaria Bioscience's Receivables history spans 11 years, with the latest figure at $88044.0 for Q4 2025.

  • For Q4 2025, Receivables fell 73.12% year-over-year to $88044.0; the TTM value through Nov 2025 reached $88044.0, down 73.12%, while the annual FY2025 figure was $432371.0, 98.29% up from the prior year.
  • Receivables for Q4 2025 was $88044.0 at Lexaria Bioscience, down from $432371.0 in the prior quarter.
  • Across five years, Receivables topped out at $954097.0 in Q2 2021 and bottomed at $88044.0 in Q4 2025.
  • The 5-year median for Receivables is $334953.0 (2021), against an average of $354544.1.
  • The largest annual shift saw Receivables skyrocketed 275.69% in 2021 before it crashed 83.77% in 2022.
  • A 5-year view of Receivables shows it stood at $461512.0 in 2021, then crashed by 37.96% to $286322.0 in 2022, then surged by 103.72% to $583290.0 in 2023, then tumbled by 43.85% to $327505.0 in 2024, then plummeted by 73.12% to $88044.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Receivables are $88044.0 (Q4 2025), $432371.0 (Q3 2025), and $358129.0 (Q2 2025).